IGC Pharma reports Q3 results
- IGC Pharma press release (IGC): Q3 Revenue of $0.32M.
- Net loss attributable to common stockholders was approximately $2.046 million for the three months ended September 30, 2026, compared to $1.821 million for the three months ended September 30, 2025. Basic and diluted net loss per share was $0.02
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.